Calton & Associates Inc. Buys New Stake in NeoGenomics, Inc. (NASDAQ:NEO)
Other hedge funds also recently made changes to their positions in the company. Lindbrook Capital LLC bought a new stake in NeoGenomics in the 4th quarter worth approximately $84,000. OLD Mission Capital LLC purchased a new position in shares of NeoGenomics in the fourth quarter valued at $675,000. Swiss National Bank increased its position in NeoGenomics by 3.7% in the fourth quarter. Swiss National Bank now owns 256,800 shares of the medical research company’s stock worth $8,762,000 after purchasing an additional 9,200 shares during the last quarter. State of New Jersey Common Pension Fund D raised its stake in NeoGenomics by 7.8% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 75,331 shares of the medical research company’s stock valued at $2,570,000 after purchasing an additional 5,445 shares in the last quarter. Finally, Two Sigma Advisers LP bought a new position in NeoGenomics during the third quarter valued at $338,000. Institutional investors and hedge funds own 95.03% of the company’s stock.
NEO stock opened at $8.94 on Monday. The company has a market capitalization of $1.12 billion, a PE ratio of -27.94 and a beta of 0.85. The company has a debt-to-equity ratio of 0.50, a current ratio of 7.93 and a quick ratio of 7.64. NeoGenomics, Inc. has a 12 month low of $6.85 and a 12 month high of $54.74. The firm’s 50-day moving average is $8.47 and its 200 day moving average is $15.79.
NeoGenomics (NASDAQ:NEO – Get Rating) last issued its earnings results on Wednesday, April 27th. The medical research company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). NeoGenomics had a negative return on equity of 6.62% and a negative net margin of 7.33%. The company had revenue of $117.17 million for the quarter, compared to analysts’ expectations of $116.44 million. During the same period last year, the business posted ($0.06) earnings per share. The business’s revenue was up 1.4% compared to the same quarter last year. Sell-side analysts forecast that NeoGenomics, Inc. will post -1.03 EPS for the current fiscal year.
Several analysts have recently issued reports on the stock. Needham & Company LLC decreased their target price on shares of NeoGenomics from $29.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, March 29th. Benchmark decreased their price objective on NeoGenomics from $26.00 to $16.00 in a research report on Tuesday, March 29th. SVB Leerink dropped their target price on NeoGenomics from $45.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, March 29th. Stephens lowered NeoGenomics from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $34.00 to $16.00 in a report on Tuesday, March 29th. Finally, Piper Sandler began coverage on shares of NeoGenomics in a research note on Thursday, June 2nd. They set an “overweight” rating and a $13.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $20.82.
About NeoGenomics (Get Rating)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
Recommended Stories
- Get a free copy of the StockNews.com research report on NeoGenomics (NEO)
- Five Below Stock is a Recession Play
- Here’s How to Dollar Cost Average into Positions in a Bear Market
- MarketBeat: Week in Review 7/4 – 7/8
- Levi Strauss Proves Resilient For Dividend Investors
- AT&T (NYSE:T) Is Its Cheaper Valuation Worth A Buy?
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO – Get Rating).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source